FDG-PET/CT in lung cancer: An update

Frontiers of Radiation Therapy and Oncology

Volumn 42, Issue , 2010, Pages 15-45

  Baum, Richard P ^a   Świȩtaszczyk, Cyprian ^a   Prasad, Vikas ^a  

^a Zentralklinik Bad Berka ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUORODEOXYGLUCOSE F 18;

CANCER SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LUNG SCINTISCANNING; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77949381938     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000262458     Document Type: Review

References (171)

1. Spaepen K, Stroobants S, Dupont P, et al: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
2. Bunyaviroch T, Coleman RE: PET evaluation of lung cancer. J Nucl Med 2006;47:451-469.
3. Lee JKT SS, Stanley RJ, Heiken JP: Computed Body Tomography with MRI Correlation, ed 3. Philadelphia, Lippincott Williams & Wilkins, 1998.
4. Hoffmann H, Dienemann H: Der Pulmonale Rundherd: Prinzipien der Diagnostik. Dt Arzteblatt 2000;97:A1065-A1071.
5. Jeong YJ, Yi CA, Lee KS: Solitary pulmonary nodules: detection, characterization, and guidance for further diagnostic workup and treatment. AJR Am J Roentgenol 2007;188:57-68.
6. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A: Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 2005;43:1-21, ix.
7. Gambhir SS, Shepherd JE, Shah BD, et al: Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-2125.
8. Proto AV, Thomas SR: Pulmonary nodules studied by computed tomography. Radiology 1985; 156:149-153.
9. Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE: Lung nodule enhancement at CT: prospective findings. Radiology 1996;201:447-455.
10. Takamochi K, Yoshida J, Murakami K, et al: Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235-242.
11. Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS: CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol 2002;178:1053-1057.
12. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF : FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000;175:245-249.
13. Gould MK, Lillington GA: Strategy and cost in investigating solitary pulmonary nodules. Thorax 1998;53(suppl 2):S32-S37.
14. Yankelevitz DF, Henschke CI: Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol 1997;168:325-328.
15. Grills IS, Yan D, Black QC, Wong CY, Martinez AA, Kestin LL: Clinical implications of defining the gross tumor volume with combination of CT and (18)FDG-positron emission tomography in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:709-719.
16. Gurney JW: Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. I. Theory. Radiology 1993;186: 405-413.
17. Bryant AS, Cerfolio RJ: The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82: 1016-1020.
18. Hashimoto Y, Tsujikawa T, Kondo C, et al: Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2006;47:426-431.
19. Slomka PJ, Dey D, Przetak C, Aladl UE, Baum RP: Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT. J Nucl Med 2003;44:1156-1167.
20. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285:914-924.
21. Albes JM, Lietzenmayer R, Schott U, Schulen E, Wehrmann M, Ziemer G: Improvement of nonsmall- cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg 1999;47:42-47.
22. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM: Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors: basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 2001;55:367-377.
23. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT: Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose: The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:698-703.
24. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE: Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-887.
25. Lowe VJ, Duhaylongsod FG, Patz EF, et al: Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202:435-439.
26. Lowe VJ, Fletcher JW, Gobar L, et al: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-1084.
27. Menda Y, Bushnell DL, Madsen MT, McLaughlin K, Kahn D, Kernstine KH: Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl Med Commun 2001;22:1077-1081.
28. Pitman AG, Hicks RJ, Binns DS, et al: Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses. Br J Radiol 2002;75:114-121.
29. Prauer HW, Weber WA, Romer W, Treumann T, Ziegler SI, Schwaiger M: Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998; 85:1506-1511.
30. Sazon DA, Santiago SM, Soo Hoo GW, et al: Fluorodeoxyglucose- positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-421.
31. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF: Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997;12:92-97.
32. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN: FDG-PET as a 'metabolic biopsy' tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med 2001;28: 1336-1340.
33. Halter G, Storck M, Guhlmann A, Frank J, Grosse S, Liewald F: FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions. Thorac Cardiovasc Surg 2000;48:97-101.
34. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH: Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001;21:1375-1378.
35. Imdahl A, Reinhardt MJ, Nitzsche EU, et al: Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385: 129-134.
36. Knight SB, Delbeke D, Stewart JR, Sandler MP: Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109:982-988.
37. Bury T, Dowlati A, Paulus P, et al: Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9: 410-414.
38. Croft DR, Trapp J, Kernstine K, et al: FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
39. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K: Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997;112:416-422.
40. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG: Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-139; discussion 9-40.
41. Gupta NC, Graeber GM, Rogers JS 2nd, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of nonsmall cell lung cancer. Ann Surg 1999;229: 286-291.
42. Lejeune C, Al Zahouri K, Woronoff-Lemsi MC, et al: Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule. Eur J Health Econ 2005;6:203-214.
43. Chhajed PN, Bernasconi M, Gambazzi F, et al: Combining bronchoscopy and positron emission tomography for the diagnosis of the small pulmonary nodule < or = 3 cm Chest 2005; 128: 3558- 3564
44. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al: Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005;171: 1378-1383.
45. Coleman RE, Laymon CM, Turkington TG: FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. Radiology 1999;210:823-828.
46. Hubner KF, Buonocore E, Gould HR, et al: Differentiating benign from malignant lung lesions using 'quantitative' parameters of FDG PET images. Clin Nucl Med 1996;21:941-949.
47. Cerfolio R, Bryant A, Ohja B: The maximum standardised uptake values on positron emission tomography of non-small cell lung cancer predict stage,recurrence and survival. J Thorac Cardiovasc Surg 2005;130:151-159.
48. Yi CA, Lee KS, Kim BT, et al: Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-450.
49. Fletcher JW, Kymes SM, Gould M, et al: A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008;49:179-185.
50. Pauls S, Buck AK, Halter G, et al: Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions: results from a large prospective clinical trial. Mol Imaging Biol 2008;10:121-128.
51. Sider L, Horejs D: Frequency of extrathoracic metastases from bronchogenic carcinoma in patients with normal-sized hilar and mediastinal lymph nodes on CT. AJR Am J Roentgenol 1988; 151:893-895.
52. Oliva JP, Pimentel G, Borron M, et al: Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer. Rev Esp Med Nucl 2001;20: 282-288.
53. Sandler MA, Pearlberg J, Madrazo B, Gitschlag K, Gross S: Computed tomography evaluation of the adrenal gland in the preoperative assessment of bronchogenic carcinoma. Radiology 1982;145: 733-736.
54. Remer EM, Obuchowski N, Ellis JD, Rice TW, Adelstein DJ, Baker ME: Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis. AJR Am J Roentgenol 2000;174: 1033-1039.
55. Li M, Liu N, Hu M, et al: Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer 2009;63:383-386.
56. Vesselle H, Salskov A, Turcotte E, et al: Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971-978.
57. Al-Sarraf N, Gately K, Lucey J, et al: Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 2008;34:892-897.
58. Vansteenkiste JF: Imaging in lung cancer: positron emission tomography scan. Eur Respir J Suppl 2002;35:49s-60s.
59. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P: PET-FDG scan enhances but does not replace preoperative surgical staging in nonsmall cell lung carcinoma. Eur J Cardiothorac Surg 2001;20:468-474;discussion 74-75.
60. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF: Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000;20:2189-2192.
61. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261.
62. Collins BT, Lowe VJ, Dunphy FR: Initial evaluation of pulmonary abnormalities: CT-guided fine-needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol 2000;22:92-96.
63. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359: 1388-1393.
64. De Wever W, Ceyssens S, Mortelmans L, et al: Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23-32.
65. Shim SS, Lee KS, Kim BT, et al: Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019.
66. Pozo-Rodriguez F, Martin de Nicolas JL, Sanchez- Nistal MA, et al : Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 2005;23:8348-8356.
67. Kumar R, Xiu Y, Yu JQ, et al: 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004;45:2058-2062.
68. Nestle U, Hellwig D, Schmidt S, et al: 2-Deoxy-2- [18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imaging Biol 2002;4:257-263.
69. Eschmann SM, Friedel G, Paulsen F, et al: FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-808.
70. Mac Manus MP, Hicks RJ, Ball DL, et al: F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
71. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P: Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-1247.
72. Kramer H, Post WJ, Pruim J, Groen HJ: The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer 2006;52:213-217.
73. Nguyen XC, Lee WW, Chung JH, et al: FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007; 62:214-219.
74. Davies A, Tan C, Paschalides C, et al: FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007;55:75-78.
75. Ohtsuka T, Nomori H, Watanabe K, et al: Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-2473.
76. Yi CA, Shin KM, Lee KS, et al: Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008;248:632-642.
77. Bury T, Dowlati A, Paulus P, et al: Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-2534.
78. Berlangieri SU, Scott AM, Knight SR, et al: F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999; 16(suppl 1):S25-S30.
79. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al: The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-324.
80. Vansteenkiste J, Dooms C: Positron emission tomography in nonsmall cell lung cancer. Curr Opin Oncol 2007;19:78-83.
81. Chin R Jr, Ward R, Keyes JW, et al: Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090-2096.
82. Diederich S, Das M: Solitary pulmonary nodule: detection and management. Cancer Imaging 2006;6:S42-S46.
83. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr: Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000;215:886-890.
84. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder- Plassmann L, Reske SN: Lymph node staging in non-small cell lung cancer: evaluation by [18F] FDG positron emission tomography (PET). Thorax 1997;52:438-441.
85. Gupta NC, Graeber GM, Bishop HA: Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (3 cm) lymph node lesions. Chest 2000;117:773-778.
86. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR: Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521-527.
87. Higashi K, Nishikawa T, Seki H, et al: Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9-15.
88. Kernstine KH, McLaughlin KA, Menda Y, et al: Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002;73:394-401;discussion 402.
89. Kernstine KH, Stanford W, Mullan BF, et al: PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-1028.
90. Liewald F, Grosse S, Storck M, et al: How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? Thorac Cardiovasc Surg 2000;48:93-96.
91. Magnani P, Carretta A, Rizzo G, et al: FDG/PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino) 1999;40:741-748.
92. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-809.
93. Patz EF Jr, Connolly J, Herndon J: Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 2000;174:769-774.
94. Roberts PF, Follette DM, von Haag D, et al: Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000;70:1154-1159; discussion 9-60.
95. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ: Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-648.
96. Steinert HC, Hauser M, Allemann F, et al: Nonsmall cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-446.
97. Tatsumi M, Yutani K, Watanabe Y, et al: Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999;40:566-573.
98. Valk PE, Pounds TR, Hopkins DM, et al: Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-1581; discussion 81-82.
99. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-2149.
100. Eubank WB, Mankoff DA, Vesselle HJ, et al: Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002;22:5-17.
101. von Haag DW, Follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM: Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002;103:160-164.
102. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL: Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536.
103. Weber WA, Dietlein M, Hellwig D, Kirsch CM, Schicha H, Schwaiger M: PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin 2003;42:135-144.
104. Baum RP, Hellwig D, Mezzetti M: Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 2004;48:119-142.
105. Bruzzi JF, Munden RF: PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-136.
106. Halpern BS, Schiepers C, Weber WA, et al: Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-2297.
107. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron- emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507.
108. Kayani I, Groves AM, Ell PJ, George PJ, Bomanji J: Imaging bronchial carcinoma in situ: possible roles for combined positron emission tomography (PET)-CT. Lancet Oncol 2005;6:190.
109. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 2005;79:263-268.
110. Yasufuku K, Nakajima T, Motoori K, et al: Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006;130:710-718.
111. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS: The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006;29:26-29.
112. Yang W, Fu Z, Yu J, et al: Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 2008;61:35-43.
113. Gilman MD, Aquino SL: State-of-the-Art FDGPET imaging of lung cancer. Semin Roentgenol 2005;40:143-153.
114. Schmucking M, Baum RP, Griesinger F, et al: Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Rec Results Cancer Res 2003;162:195-202.
115. Bosmans G, van Baardwijk A, Dekker A, et al: Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2006;66:748-753.
116. Mah K, Caldwell CB, Ung YC, et al: The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-350.
117. Rosenman J, Chaney EL, Sailer S, et al: Recent advances in radiotherapy treatment planning Cancer Invest 1991;9:465-481.
118. Touboul E, Deniaud-Alexandre E, Moureau- Zabotto L, Lerouge D: The impact of integrating images of positron emission tomography with computed tomography simulation on radiation therapy planning. Cancer Radiother 2004;8(suppl 1):S29-S35.
119. Lavrenkov K, Partridge M, Cook G, Brada M: Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005;77:1-4.
120. Messa C, Ceresoli GL, Rizzo G, et al: Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging 2005;49:259-266.
121. Brianzoni E, Rossi G, Ancidei S, et al: Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005;32:1392-1399.
122. De Ruysscher D, Wanders S, Minken A, et al: Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005;77:5-10.
123. De Ruysscher D, Wanders S, van Haren E, et al: Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-smallcell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-994.
124. Senan S, De Ruysscher D: Critical review of PETCT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol 2005;56:345-351.
125. Nestle U, Schaefer-Schuler A, Kremp S, et al: Target volume definition for (18)F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006.
126. Biehl KJ, Kong F-M, Dehdashti F, et al: 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 2006;47:1808-1812.
127. Cherk MH, Foo SS, Poon AM, et al: Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921-1926.
128. Nestle U, Kremp S, Grosu AL: Practical integration of [(18)F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006;81:209-225.
129. Visser EP, Philippens ME, Kienhorst L, et al: Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET. J Nucl Med 2008;49:892-898.
130. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909;discussion 9.
131. Eschmann SM, Friedel G, Paulsen F, et al: Repeat (18)F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007;55:165-171.
132. Baum RP, Griesinger F, Niesen A: Correlation of FDG-PET measurements with morphometric tumor response after induction chemotherapy and adjuvant radiotherapz in stage III non-small cell lung cancer (NSCLC). 25th Int Symp Radioactive Isotopes in Clinical Medicine and Research, Bad Gastein, 2002.
133. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-187.
134. Akhurst T, Downey RJ, Ginsberg MS, et al: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259-264;discussion 64-66.
135. Pottgen C, Levegrun S, Theegarten D, et al: Value of 18F-fluoro-2-deoxy- D-glucose-positron emission tomography/computed tomography in nonsmall- cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-106.
136. Su H, Bodenstein C, Dumont RA, et al: Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-5667.
137. Weber WA, Petersen V, Schmidt B, et al: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
138. Cerfolio RJ, Bryant AS, Ojha B: Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131: 1229-1235.
139. Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ: Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004;128: 892-899.
140. Schmucking M, Baum RP, Bonnet R, Junker K, Muller KM: Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 2005;26:178-189.
141. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW: Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007;48:744-751.
142. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G: Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable nonsmall- cell lung cancer. J Clin Oncol 2008;26:4610-4616.
143. Poettgen C, Theegarten D, Eberhardt W, et al: Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007;73:316-323.
144. Vesselle H, Freeman JD, Wiens L, et al: Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-3263.
145. Talbot JN, Kerrou K, Grahek D, et al: PET in primary pulmonary or pleural cancer. Presse Med 2006;35:1387-1400.
146. Schaffler GJ, Wolf G, Schoellnast H, et al: Nonsmall cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 2004;231:858-865.
147. Shim SS, Lee KS, Kim BT, et al: Integrated PET/ CT and the dry pleural dissemination of peripheral adenocarcinoma of the lung: diagnostic implications. J Comput Assist Tomogr 2006;30: 70-76.
148. Truong MT, Marom EM, Erasmus JJ: Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 2006;21:146-153.
149. Alzahouri K, Lejeune C, Woronoff-Lemsi MC, Arveux P, Guillemin F: Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 2005;60:479-492.
150. Dietlein M, Moka D, Weber K, Theissen P, Schicha H: Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data. Nuklearmedizin 2001;40: 122-128.
151. Dietlein M, Weber K, Gandjour A, et al: Costeffectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27:1598-1609.
152. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J: Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-1436.
153. Nguyen VH, Peloquin S, Lacasse Y: Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. Can Respir J 2005; 12:19-25.
154. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S: Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F] fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (nonsmall cell lung carcinoma) in Japan. Chest 2000; 117:346-353.
155. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S: Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002;16:263-271.
156. Scott WJ, Shepherd J, Gambhir SS: Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998;66:1876-1883; discussion 83-85.
157. Pompen M, Gok M, Novak A, et al: Direct costs associated with the disease management of patients with unresectable advanced non-smallcell lung cancer in The Netherlands. Lung Cancer 2009;64:110-116.
158. Abrams J, Doyle LA, Aisner J: Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988;15:261-277.
159. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA: Seeking a home for a PET, part 2:Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125:2300-2308.
160. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC: Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-1917.
161. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA: Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22: 3248-3254.
162. Kruger S, Buck AK, Blumstein NM, et al: Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 2006;260:545-550.
163. Fischer BM, Mortensen J, Langer SW, et al: PET/ CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 2006; 54:41-49.
164. Brink I, Schumacher T, Mix M, et al: Impact of [18F]FDG-PET on the primary staging of smallcell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-1620.
165. Fischer BM, Mortensen J, Langer SW, et al: A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-345.
166. Kut V, Spies W, Spies S, Gooding W, Argiris A: Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50.
167. Niho S, Fujii H, Murakami K, et al: Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007;57:328-333.
168. De Leyn P, Lardinois D, Van Schil PE, et al: ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:1-8.
169. Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z: F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000;25:273-278.
170. Gupta NC, Maloof J, Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37: 943-948.
171. Vesselle H, Pugsley JM, Vallieres E, Wood DE: The impact of fluorodeoxyglucose F 18 positronemission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;124:511-519.